Management consensus guidance for the use of rivaroxaban - an oral, direct factor Xa inhibitor

Thrombosis and Haemostasis

Volumn 108, Issue 5, 2012, Pages 876-886

  Turpie, Alexander G G ^a   Kreutz, Reinhold ^b   Llau, Juan ^c   Norrving, Bo ^d   Haas, Sylvia ^e  

^a MCMASTER UNIVERSITY   (Canada)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

^e TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Anticoagulant; Practical management; Recommendations; Rivaroxaban

Indexed keywords

AMIODARONE; APIXABAN; ATORVASTATIN; BLOOD CLOTTING FACTOR 10A; CARBAMAZEPINE; CLARITHROMYCIN; DABIGATRAN; DABIGATRAN ETEXILATE; DIGOXIN; ENOXAPARIN; ERYTHROMYCIN; FLUCONAZOLE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; HYPERICUM PERFORATUM EXTRACT; ITRACONAZOLE; KETOCONAZOLE; LOW MOLECULAR WEIGHT HEPARIN; MIDAZOLAM; PHENOBARBITAL; PHENYTOIN; PLACEBO; POSACONAZOLE; RIFAMPICIN; RIVAROXABAN; VERAPAMIL; VORICONAZOLE; WARFARIN;

ACUTE CORONARY SYNDROME; ARTICLE; BLEEDING; BODY WEIGHT; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; DEEP VEIN THROMBOSIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; HEART ATRIUM FIBRILLATION; HUMAN; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; LUNG EMBOLISM; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; RECURRENT DISEASE; THROMBOEMBOLISM; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; BLOOD LOSS, SURGICAL; CLINICAL TRIALS AS TOPIC; FACTOR XA; FEMALE; HUMANS; MALE; MORPHOLINES; PRACTICE GUIDELINES AS TOPIC; PREGNANCY; STROKE; THIOPHENES; VENOUS THROMBOEMBOLISM; VENOUS THROMBOSIS; WARFARIN;

EID: 84870032549     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH12-03-0209     Document Type: Article

References (53)

1. Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines (9th Edition). Chest 2012; 141: e278S-e325S.
2. Hamm CW, Bassand J P, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the Management of Acute Coronary Syndromes (ACS) in Patients Presenting without Persistent ST-segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 2011; 32: 2999-3054.
3. Lansberg MG, O'Donnell MJ, Khatri P, et al. Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e601S-e636S.
4. Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008; 358: 2765-2775.
5. Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008; 372: 31-39.
6. Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for throm-boprophylaxis after total knee arthroplasty. N Engl J Med 2008; 358: 2776-2786.
7. Turpie AGG, Lassen MR, Davidson BL, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009; 373: 1673-1680.
8. The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous throm-boembolism. N Engl J Med 2010; 363: 2499-2510.
9. The EINSTEIN-PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366: 1287-1297.
10. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvu-lar atrial fibrillation. N Engl J Med 2011; 365: 883-891.
11. Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012; 366: 9-19.
12. Rosencher N, Bonnet M P, Sessler DI. Selected new antithrombotic agents and neuraxial anaesthesia for major orthopaedic surgery: management strategies. Anaesthesia 2007; 62: 1154-1160.
13. ® (rivaroxaban) Summary of Product Characteristics. 2012. Available at: http://www.xarelto.com/html/downloads/Xarelto-Prescrib ing_Information-May-2012.pdf. Accessed July 31, 2012.
14. Kubitza D, Becka M, Voith B, et al. Safety, pharmacodynamics, and pharmacoki-netics of single doses of BAY 59-7939, an oral, direct Factor Xa inhibitor. Clin Pharmacol Ther 2005; 78: 412-421.
15. Kubitza D, Becka M, Roth A, et al. Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects. Curr Med Res Opin 2008; 24: 2757-2765.
16. Gogarten W, Vandermeulen E, Va n Aken H, et al. Regional anaesthesia and anti-thrombotic agents: recommendations of the European Society of Anaesthesiol-ogy. Eur J Anaesthesiol 2010; 27: 999-1015.
17. Ageno W, Gallus AS, Wittkowsky A, et al. Oral anticoagulant therapy: antithrom-botic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012; 141: e44S-e88S.
18. Kubitza D, Becka M, Voith B, et al. Effect of enoxaparin on the safety, tolerability, pharmacodynamics and pharmacokinetics of BAY 59-7939 - an oral, direct Factor Xa inhibitor. J Thromb Haemost 2005; 3 (Suppl 1): Abstract P1704.
19. Garcia DA, Baglin T P, Weitz JI, et al. Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines (9th Edition). Chest 2012; 141: e24S-e43S.
20. Heni N, Glogner P. Pharmacokinetics of phenprocoumon in man investigated using a gas chromatographic method of drug analysis. Naunyn-Schmiedeberg's Arch Pharmacol 1976; 293: 183-186.
21. Boehringer Ingelheim International GmbH. Pradaxa (dabigatran etexilate) Summary of Product Characteristics. 2012. Available at: http://www.ema.europa.eu/ docs/en_GB/document_library/Other/2012/05/WC500127777.pdf. Accessed August 2, 2012.
22. Huisman M V, Lip GY, Diener HC, et al. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: Resolving uncertainties in routine practice. Thromb Haemost 2012; 107: 838-847.
23. Haas S, Spannagl M, Schellong S. Novel oral anticoagulants - key messages for the angiologist. Vasa 2012; 41: 177-191.
24. Kubitza D, Becka M, Zuehlsdorf M, et al. No interaction between the novel, oral direct Factor Xa inhibitor BAY 59-7939 and digoxin. J Clin Pharmacol 2006; 46: 702: Abstract 11.
25. Kubitza D, Becka M, Mueck W, et al. Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban - an oral, direct Factor Xa inhibitor - are not affected by aspirin. J Clin Pharmacol 2006; 46: 981-990.
26. Kubitza D, Becka M, Mueck W, et al. Rivaroxaban (BAY 59-7939) - an oral, direct Factor Xa inhibitor - has no clinically relevant interaction with naproxen. Br J Clin Pharmacol 2007; 63: 469-476.
27. Kubitza D, Mueck W, Becka M. No interaction between rivaroxaban - a novel, oral, direct Factor Xa inhibitor - and atorvastatin. Pathophysiol Haemost Thromb 2008; 36: A40: Abstract P062.
28. Kubitza D, Becka M, Mueck W, et al. Effect of co-administration of rivaroxaban and clopidogrel on bleeding time, pharmacodynamics and pharmacokinetics: a phase I study. Pharmaceuticals 2012; 5: 279-296.
29. López-Jiménez L, Montero M, González-Fajardo JA, et al. Venous thromboem-bolism in very elderly patients: findings from a prospective registry (RIETE). Haematologica 2006; 91: 1046-1051.
30. Spencer FA, Gore JM, Lessard D, et al. Venous thromboembolism in the elderly. A community-based perspective. Thromb Haemost 2008; 100: 780-788.
31. Glassock RJ, Winearls C. Ageing and the glomerular filtration rate: truths and consequences. Trans Am Clin Climatol Assoc 2009; 120: 419-428.
32. Turpie AGG, Lassen MR, Eriksson BI, et al. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. Thromb Haemost 2011; 105: 444-453.
33. Kubitza D, Becka M, Roth A, et al. The influence of age and gender on the pharma-cokinetics and pharmacodynamics of rivaroxaban - an oral, direct Factor Xa inhibitor. J Clin Pharmacol 2012; in press.
34. Weinz C, Schwarz T, Kubitza D, et al. Metabolism and excretion of rivaroxaban, an oral, direct Factor Xa inhibitor, in rats, dogs and humans. Drug Metab Dispos 2009; 37: 1056-1064.
35. Kubitza D, Becka M, Mueck W, et al. Effects of renal impairment on the phar-macokinetics, pharmacodynamics and safety of rivaroxaban - an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol 2010; 70: 703-712.
36. Halabi A, Kubitza D, Zuehlsdorf M, et al. Effect of hepatic impairment on the pharmacokinetics, pharmacodynamics and tolerability of rivaroxaban - an oral, direct Factor Xa inhibitor. J Thromb Haemost 2007; 5 (Suppl 2): Abstract P-M-635.
37. Baker RI, Coughlin PB, Gallus AS, et al. Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis. Med J Aust 2004; 181: 492-497.
38. Hanley J P. Warfarin reversal. J Clin Pathol 2004; 57: 1132-1139.
39. Garcia DA, Baglin T P, Weitz JI, et al. Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012; 141: e24S-e43S.
40. Eerenberg ES, Kamphuisen PW, Sijpkens MK, et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011; 124: 1573-1579.
41. Marlu R, Hodaj E, Paris A, et al. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban. A randomised crossover ex vivo study in healthy volunteers. Thromb Haemost 2012; 108: 217-224.
42. Kubitza D, Becka M, Wensing G, et al. Safety, pharmacodynamics, and phar-macokinetics of BAY 59-7939 - an oral, direct Factor Xa inhibitor - after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 2005; 61: 873-880.
43. Mueck W, Becka M, Kubitza D, et al. Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban - an oral, direct Factor Xa inhibitor - in healthy subjects. Int J Clin Pharmacol Ther 2007; 45: 335-344.
44. Mueck W, Eriksson BI, Bauer KA, et al. Population pharmacokinetics and phar-macodynamics of rivaroxaban - an oral, direct Factor Xa inhibitor - in patients undergoing major orthopaedic surgery. Clin Pharmacokinet 2008; 47: 203-216.
45. Gerotziafas GT, Hatmi M, Samama MM, et al. Optimisation of the assays for the measurement of clotting factor activity in the presence of rivaroxaban. Thromb Res 2012; 129: 101-103.
46. Ma n i H, Hesse C, Stratmann G, et al. Rivaroxaban differentially influences ex vivo global coagulation assays based on the administration time. Thromb Haemost 2011; 106: 156-164.
47. Asmis LM, Alberio L, Angelillo-Scherrer A, et al. Rivaroxaban: quantification by anti-FXa assay and influence on coagulation tests: a study in 9 Swiss laboratories. Thromb Res 2012; 129: 492-498.
48. Freyburger G, Macouillard G, Labrouche S, et al. Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: two observational studies in patients undergoing total hip or total knee replacement. Thromb Res 2011; 127: 457-465.
49. Tichelaar V, de Jong H, Nijland H, et al. Interference of rivaroxaban in one-stage and chromogenic factor VIII:C assays. Thromb Haemost 2011; 106: 990-992.
50. Merriman E, Kaplan Z, Butler J, et al. Rivaroxaban and false positive lupus anti -coagulant testing. Thromb Haemost 2011; 105: 385-386.
51. Lindhoff-Last E, Samama M M, Ortel TL, et al. Assays fo r measu ring riva roxaban: their suitability and limitations. Ther Drug Monit 2010; 32: 673-679.
52. Samama MM, Martinoli JL, Le Flem L, et al. Assessment of laboratory assays to measure rivaroxaban - an oral, direct Factor Xa inhibitor. Thromb Haemost 2010; 103: 815-825.
53. Samama MM, Contant G, Spiro TE, et al. Evaluation of the anti-Factor Xa chro-mogenic assay for measuring rivaroxaban plasma concentrations using calibrators and controls. Blood (ASH Annual Meeting Abstracts) 2010; 116: 1363-1364 (Abstract 3330).